Regeneus

Sinead Blaber, Ph.D., Director of Clinical Development and Medical Affairs

Paddington, Australia

(ASX: RGS)

Virtual Presentation

Regeneus is a clinical-stage biotech company developing innovative first-in-class stem cell and bioactive therapies that address significant unmet medical needs. Our lead product Progenza™ is a cellular therapy comprised of allogeneic mesenchymal stem cells and the bioactive MSC secretome that has shown the potential to be a blockbuster first-in-class and best-in-class disease modifying osteoarthritis drug. In a human safety and efficacy study for knee OA, Progenza™ demonstrated safety, long-term pain relief, functional improvement, and inhibition of OA structural disease progression. We are planning Phase II trials of Progenza in the U.S. and Japan to commence in 2022. Our second product, Sygenus, is a cell-free therapy comprised of the allogeneic bioactive MSC secretome. Sygenus is a platform technology with broad potential therapeutic applications in topical pain, inflammation, dermatitis, diabetic neuropathy, postherpetic neuralgia, burns, wounds, ulcers, radiation injury, and aesthetic dermatology.

www.regeneus.com.au



By using this website you agree to accept our Privacy Policy and Terms & Conditions